← Leaderboards
Neil Harrison Bander
Weill Medical College Of Cornell Univ
$380,857
Attributed
$380,857
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$380,857 · 4
By mechanism
M01$380,857 · 4
Top collaborators
No co-investigators on record.
Most similar at Weill Medical College Of Cornell Univ
Same institution · by research overlap
- David Charles Lyden$14,066,044
- David M. Nanus$4,374,762
- Andrew J Dannenberg$7,046,240
- Xin-Yun Huang$18,104,181
- John P Moore$51,152,802
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationHuman SubjectMonoclonal AntibodyClinical ResearchNeoplasm /Cancer ImmunotherapyProstate NeoplasmsProstate Specific AntigenClinical Trial Phase IDrug Screening /EvaluationNeoplasm /Cancer Relapse /RecurrencePatient Oriented ResearchPharmacokineticsRadionuclidesRadiotracerAntigen Antibody ReactionRenal Cell CarcinomaAntineoplasticsClinical TrialsCytotoxicityDosageIodineMaleMetastasisNeoplasm /Cancer Pharmacology
Grant awards (5)
Ph. I humanized mAb huJ591-DOTA-177Lu/ relapsed prostate cancer$142,282
M01 · FY2004 · RR
MONOCLONAL ANTIBODY MUJ591 PATIENTS W/ HORMONE INDEPENDANT PROSTATE CANCER$0
M01 · FY2001 · RR
PHASE 1 TRIAL OF MONOCLONAL ANTIBODY F31 IN RENAL CANCER$79,525
M01 · FY2000 · RR
PHASE I/II/ 131 IODINE MAB PROST 30/PATIENTS W/ADVANCED PROSTATE CANCER$79,525
M01 · FY2000 · RR
MONOCLONAL ANTIBODY MUJ591 PATIENTS W/ HORMONE INDEPENDANT PROSTATE CANCER$79,525
M01 · FY2000 · RR